Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
agreed, Andreeff, attention, binding, bring, Concurrent, consideration, customary, deal, Deposit, focused, group, journal, Keystone, led, lesser, line, Lux, Michael, mutationally, outlined, ownership, path, progression, recommended, resale, respond, RSU, set, Tuesday, Tus, TusVen, Ven, webcast
Removed:
contractor, Ontario, pharmaceutical
Filing tables
Filing exhibits
Related press release
Associated APTO transcripts
APTO similar filings
Filing view
External links
Exhibit 32.2
Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Fletcher Payne, the Senior Vice President and Chief Financial Officer of Aptose Biosciences Inc. (the “Company”), hereby certify that, to my knowledge:
1.
The Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 (the “Report”) of the Company fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and
2.
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company
Date: August 10, 2023
/s/ Fletcher Payne Name: Fletcher Payne Title: Senior Vice President and Chief Financial Officer |